Compare GKOS & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | BIO |
|---|---|---|
| Founded | 1998 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Medical/Dental Instruments | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 7.1B |
| IPO Year | 2015 | N/A |
| Metric | GKOS | BIO |
|---|---|---|
| Price | $141.22 | $254.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $126.92 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 642.1K | 241.5K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $2.74 |
| Revenue Next Year | $27.43 | $3.20 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $211.43 |
| 52 Week High | $145.50 | $343.12 |
| Indicator | GKOS | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 73.45 | 33.87 |
| Support Level | $80.14 | $246.01 |
| Resistance Level | N/A | $289.61 |
| Average True Range (ATR) | 4.95 | 10.43 |
| MACD | 1.69 | -3.76 |
| Stochastic Oscillator | 86.28 | 17.46 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.